Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00921310 · ClinicalTrials.gov registry record · Phase 1
Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00921310 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 12 participants.
The verdict
NCT00921310, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of the combination of temsirolimus and pemetrexed, as well as the response rate. The starting dose (Dose Level 1) and schedule of pemetrexed will be 500 mg/m\^2 given every 3 weeks and the starting dose (Dose Level 1) for temsirolimus will be 15 mg given weekly for 3 weeks, to complete 1 cycle. In subsequent cohorts, dose will be escalated or de-escalated. Enrollment to each cohort is based on toxicity experienced at that dose level.
Interventions
- DRUG Pemetrexed
- DRUG Temsirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-09 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00921310
The ClinicalTrials.gov registry entry for NCT00921310 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pemetrexed is the first listed.
NCT00921310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00921310 about?
NCT00921310 is a clinical study titled "Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer". To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of the combination of temsirolimus and pemetrexed, as well as the response rate. The starting dose (Dose Level 1) and schedule of pemetrexed will be 500 mg/m\^2 given every 3 weeks and the starting dose (Dose Level 1) f...
What is the current status of trial NCT00921310?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2009-09. Estimated completion is 2016-04.
What interventions are being tested in trial NCT00921310?
The interventions under investigation include: Pemetrexed (DRUG), Temsirolimus (DRUG).
Who is sponsoring clinical trial NCT00921310?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.